Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 204 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High Risk for Breast Cancer Clear all
Completed Phase 2 Interventional Results available

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

NCT00365365
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab, Bevacizumab and trastuzumab maintenance therapy, Bevacizumab maintenance therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Results available

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Adjuvant endocrine therapy, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 2, 2026, 8:42 AM EDT
Recruiting Phase 2 Interventional

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

NCT06492759
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review
Radiation · Biological · Drug + 2 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Not applicable Interventional Results available

Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities

NCT00606931
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereo Navigator Accessory to PEM Flex PET Scanner
Device
Lead sponsor
Naviscan PET Systems
Industry
Eligibility
25 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Boca Raton, Florida • Timonium, Maryland • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2009 · Synced Oct 2, 2026, 8:42 AM EDT
Active, not recruiting Not applicable Interventional

Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer

NCT02494869
View directory record Official record
Conditions
High Risk for Developing Breast Cancer
Interventions
Nonlinear Aerobic Training, Height, Weight, BMI measure, Blood draw, Cardiopulmonary exercise test
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 2, 2026, 8:42 AM EDT
Not listed Phase 2 Interventional

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

NCT00080756
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer
Interventions
therapeutic estradiol, deslorelin, therapeutic testosterone, therapeutic conventional surgery, active surveillance, quality-of-life assessment, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years to 48 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Phase 1Phase 2 Interventional

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

NCT00010283
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
5 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 2, 2026, 8:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00291083
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 2, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional

Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer

NCT04149522
View directory record Official record
Conditions
Breast Cancer, Radiotherapy; Adverse Effect, Dermatitis or Eczema, Radiotherapy Side Effect, Radiation Burn, Radiation Dermatitis, Radiotherapy; Complications
Interventions
Mepitel Film®
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Clairton, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 2, 2026, 8:42 AM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer

NCT00976339
View directory record Official record
Conditions
Breast Cancer
Interventions
Cholecalciferol
Drug
Lead sponsor
Katherine D. Crew
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 2, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

Multi-catheter High Dose Rate (HDR) Breast Brachytherapy

NCT00214149
View directory record Official record
Conditions
Breast Cancer
Interventions
brachytherapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 2, 2026, 8:42 AM EDT
Recruiting Not applicable Interventional

Researching the Effect of Exercise on Cancer

NCT04589468
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage I Colorectal Cancer, Stage II Colorectal Cancer, Stage III Colorectal Cancer
Interventions
Exercise
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Durate, California • San Carlos, California • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Phase 1 Interventional Results available

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer

NCT02063724
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2 pulsed Dendritic Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Results available

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

NCT03417544
View directory record Official record
Conditions
HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
Interventions
ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Women With Breast Cancer

NCT00003519
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
2,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
134
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 2, 2026, 8:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Patient Navigation Intervention for the Improvement of Risk Management Among Women at High Risk of Breast Cancer

NCT06950008
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Educational Intervention, Patient Navigation, Survey Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 2, 2026, 8:42 AM EDT
Not listed Not applicable Interventional

A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.

NCT01792726
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Boost to the tumour bed
Radiation
Lead sponsor
University College, London
Other
Eligibility
Female only
Enrollment
1,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Savannah, Georgia • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 2, 2026, 8:42 AM EDT
Not listed No phase listed Observational

Tear Based Sample Collection Breast Cancer Detection

NCT04974567
View directory record Official record
Conditions
Breast Cancer, Tear, Breast Cancer Female
Interventions
Schirmer Strip
Other
Lead sponsor
Namida Lab
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 2, 2026, 8:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

NCT00291096
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Carol Fabian, MD
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 2, 2026, 8:42 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia

NCT00497809
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
AVI-014 versus Filgrastim
Drug
Lead sponsor
AviGenics
Industry
Eligibility
18 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Anaheim, California • Greenbrae, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 2, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

NCT00285857
View directory record Official record
Conditions
Breast Cancer
Interventions
Lovastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 2, 2026, 8:42 AM EDT
Withdrawn Not applicable Interventional

Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease

NCT00312637
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Spectroscopy
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
25 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 2, 2026, 8:42 AM EDT